155 related articles for article (PubMed ID: 18304965)
1. A novel humanized anti-human death receptor 5 antibody CS-1008 induces apoptosis in tumor cells without toxicity in hepatocytes.
Yada A; Yazawa M; Ishida S; Yoshida H; Ichikawa K; Kurakata S; Fujiwara K
Ann Oncol; 2008 Jun; 19(6):1060-7. PubMed ID: 18304965
[TBL] [Abstract][Full Text] [Related]
2. Treatment with gemcitabine and TRA-8 anti-death receptor-5 mAb reduces pancreatic adenocarcinoma cell viability in vitro and growth in vivo.
DeRosier LC; Huang ZQ; Sellers JC; Buchsbaum DJ; Vickers SM
J Gastrointest Surg; 2006 Nov; 10(9):1291-300; discussion 1300. PubMed ID: 17114015
[TBL] [Abstract][Full Text] [Related]
3. Treatment of human colon cancer xenografts with TRA-8 anti-death receptor 5 antibody alone or in combination with CPT-11.
Oliver PG; LoBuglio AF; Zinn KR; Kim H; Nan L; Zhou T; Wang W; Buchsbaum DJ
Clin Cancer Res; 2008 Apr; 14(7):2180-9. PubMed ID: 18381960
[TBL] [Abstract][Full Text] [Related]
4. Combination with liposome-entrapped, ends-modified raf antisense oligonucleotide (LErafAON) improves the anti-tumor efficacies of cisplatin, epirubicin, mitoxantrone, docetaxel and gemcitabine.
Pei J; Zhang C; Gokhale PC; Rahman A; Dritschilo A; Ahmad I; Kasid UN
Anticancer Drugs; 2004 Mar; 15(3):243-53. PubMed ID: 15014358
[TBL] [Abstract][Full Text] [Related]
5. A combination of DR5 agonistic monoclonal antibody with gemcitabine targets pancreatic cancer stem cells and results in long-term disease control in human pancreatic cancer model.
Rajeshkumar NV; Rasheed ZA; García-García E; López-Ríos F; Fujiwara K; Matsui WH; Hidalgo M
Mol Cancer Ther; 2010 Sep; 9(9):2582-92. PubMed ID: 20660600
[TBL] [Abstract][Full Text] [Related]
6. Dual combination therapy targeting DR5 and EMMPRIN in pancreatic adenocarcinoma.
Kim H; Zhai G; Samuel SL; Rigell CJ; Umphrey HR; Rana S; Stockard CR; Fineberg NS; Zinn KR
Mol Cancer Ther; 2012 Feb; 11(2):405-15. PubMed ID: 22203731
[TBL] [Abstract][Full Text] [Related]
7. Combination treatment with TRA-8 anti death receptor 5 antibody and CPT-11 induces tumor regression in an orthotopic model of pancreatic cancer.
DeRosier LC; Buchsbaum DJ; Oliver PG; Huang ZQ; Sellers JC; Grizzle WE; Wang W; Zhou T; Zinn KR; Long JW; Vickers SM
Clin Cancer Res; 2007 Sep; 13(18 Pt 2):5535s-5543s. PubMed ID: 17875786
[TBL] [Abstract][Full Text] [Related]
8. Anti-tumor activity of an anti-DR5 monoclonal antibody, TRA-8, in combination with taxane/platinum-based chemotherapy in an ovarian cancer model.
Bevis KS; McNally LR; Sellers JC; Della Manna D; Londoño Joshi A; Amm H; Straughn JM; Buchsbaum DJ
Gynecol Oncol; 2011 Apr; 121(1):193-9. PubMed ID: 21211830
[TBL] [Abstract][Full Text] [Related]
9. Structural and functional analysis of the interaction between the agonistic monoclonal antibody Apomab and the proapoptotic receptor DR5.
Adams C; Totpal K; Lawrence D; Marsters S; Pitti R; Yee S; Ross S; Deforge L; Koeppen H; Sagolla M; Compaan D; Lowman H; Hymowitz S; Ashkenazi A
Cell Death Differ; 2008 Apr; 15(4):751-61. PubMed ID: 18219321
[TBL] [Abstract][Full Text] [Related]
10. Apoptotic activity and antitumor efficacy of PEGylated TNF-related apoptosis-inducing ligand (TRAIL) in a Mia Paca-2 cell-xenografted mouse model.
Byeon HJ; Choi SH; Choi JS; Kim TH; Lee ES; Lee KC; Youn YS
Biomed Pharmacother; 2014 Feb; 68(1):65-9. PubMed ID: 24268811
[TBL] [Abstract][Full Text] [Related]
11. TRA-8 anti-DR5 monoclonal antibody and gemcitabine induce apoptosis and inhibit radiologically validated orthotopic pancreatic tumor growth.
Derosier LC; Vickers SM; Zinn KR; Huang Z; Wang W; Grizzle WE; Sellers J; Stockard CR; Zhou T; Oliver PG; Arnoletti P; Lobuglio AF; Buchsbaum DJ
Mol Cancer Ther; 2007 Dec; 6(12 Pt 1):3198-207. PubMed ID: 18089714
[TBL] [Abstract][Full Text] [Related]
12. Combination therapy for advanced pancreatic cancer using Herceptin plus chemotherapy.
Büchler P; Reber HA; Eibl G; Roth MA; Büchler MW; Friess H; Isacoff WH; Hines OJ
Int J Oncol; 2005 Oct; 27(4):1125-30. PubMed ID: 16142331
[TBL] [Abstract][Full Text] [Related]
13. Predominant antitumor effects by fully human anti-TRAIL-receptor 2 (DR5) monoclonal antibodies in human glioma cells in vitro and in vivo.
Nagane M; Shimizu S; Mori E; Kataoka S; Shiokawa Y
Neuro Oncol; 2010 Jul; 12(7):687-700. PubMed ID: 20511188
[TBL] [Abstract][Full Text] [Related]
14. Synergistic antitumor activity of ZD6474, an inhibitor of vascular endothelial growth factor receptor and epidermal growth factor receptor signaling, with gemcitabine and ionizing radiation against pancreatic cancer.
Bianco C; Giovannetti E; Ciardiello F; Mey V; Nannizzi S; Tortora G; Troiani T; Pasqualetti F; Eckhardt G; de Liguoro M; Ricciardi S; Del Tacca M; Raben D; Cionini L; Danesi R
Clin Cancer Res; 2006 Dec; 12(23):7099-107. PubMed ID: 17145834
[TBL] [Abstract][Full Text] [Related]
15. Comparative benefits of Nab-paclitaxel over gemcitabine or polysorbate-based docetaxel in experimental pancreatic cancer.
Awasthi N; Zhang C; Schwarz AM; Hinz S; Wang C; Williams NS; Schwarz MA; Schwarz RE
Carcinogenesis; 2013 Oct; 34(10):2361-9. PubMed ID: 23803690
[TBL] [Abstract][Full Text] [Related]
16. Early therapy evaluation of combined anti-death receptor 5 antibody and gemcitabine in orthotopic pancreatic tumor xenografts by diffusion-weighted magnetic resonance imaging.
Kim H; Morgan DE; Buchsbaum DJ; Zeng H; Grizzle WE; Warram JM; Stockard CR; McNally LR; Long JW; Sellers JC; Forero A; Zinn KR
Cancer Res; 2008 Oct; 68(20):8369-76. PubMed ID: 18922909
[TBL] [Abstract][Full Text] [Related]
17. A novel anti-DR5 chimeric antibody and epirubicin synergistically suppress tumor growth.
Qiu Y; Zhang Z; Shi J; Liu S; Liu Y; Zheng D
IUBMB Life; 2012 Sep; 64(9):757-65. PubMed ID: 22815059
[TBL] [Abstract][Full Text] [Related]
18. Mechanisms of resistance to Erbitux (anti-epidermal growth factor receptor) combination therapy in pancreatic adenocarcinoma cells.
Arnoletti JP; Buchsbaum DJ; Huang ZQ; Hawkins AE; Khazaeli MB; Kraus MH; Vickers SM
J Gastrointest Surg; 2004 Dec; 8(8):960-9; discussion 969-70. PubMed ID: 15585383
[TBL] [Abstract][Full Text] [Related]
19. Molecular imaging of death receptor 5 occupancy and saturation kinetics in vivo by humanized monoclonal antibody CS-1008.
Burvenich IJ; Lee FT; Cartwright GA; O'Keefe GJ; Makris D; Cao D; Gong S; Chueh AC; Mariadason JM; Brechbiel MW; Beckman RA; Fujiwara K; von Roemeling R; Scott AM
Clin Cancer Res; 2013 Nov; 19(21):5984-93. PubMed ID: 24045184
[TBL] [Abstract][Full Text] [Related]
20. A novel agonistic antibody to human death receptor 4 induces apoptotic cell death in various tumor cells without cytotoxicity in hepatocytes.
Sung ES; Park KJ; Lee SH; Jang YS; Park SK; Park YH; Kwag WJ; Kwon MH; Kim YS
Mol Cancer Ther; 2009 Aug; 8(8):2276-85. PubMed ID: 19638452
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]